New Zealand markets closed

Aurobindo Pharma Limited (AUROPHARMA.NS)

NSE - NSE Real-time price. Currency in INR
Add to watchlist
1,211.90+4.30 (+0.36%)
As of 01:59PM IST. Market open.
Currency in INR

Valuation measures4

Market cap (intra-day) 706.65B
Enterprise value 707.21B
Trailing P/E 22.30
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.46
Price/book (mrq)2.37
Enterprise value/revenue 2.46
Enterprise value/EBITDA 11.42

Trading information

Stock price history

Beta (5Y monthly) 0.51
52-week change 369.51%
S&P500 52-week change 322.55%
52-week high 31,292.10
52-week low 3708.85
50-day moving average 31,193.70
200-day moving average 31,066.02

Share statistics

Avg vol (3-month) 31.62M
Avg vol (10-day) 31.91M
Shares outstanding 5585.17M
Implied shares outstanding 6589.95M
Float 8280.83M
% held by insiders 152.03%
% held by institutions 132.22%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 44.5
Forward annual dividend yield 40.37%
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 40.69
Payout ratio 48.31%
Dividend date 3N/A
Ex-dividend date 420 Feb 2024
Last split factor 22:1
Last split date 320 Jul 2015

Financial highlights

Fiscal year

Fiscal year ends 31 Mar 2024
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 10.94%
Operating margin (ttm)17.58%

Management effectiveness

Return on assets (ttm)6.36%
Return on equity (ttm)11.18%

Income statement

Revenue (ttm)290.02B
Revenue per share (ttm)495.04
Quarterly revenue growth (yoy)17.10%
Gross profit (ttm)N/A
EBITDA 58.43B
Net income avi to common (ttm)31.73B
Diluted EPS (ttm)54.10
Quarterly earnings growth (yoy)79.50%

Balance sheet

Total cash (mrq)63.29B
Total cash per share (mrq)108.02
Total debt (mrq)66.48B
Total debt/equity (mrq)22.27%
Current ratio (mrq)1.98
Book value per share (mrq)509.34

Cash flow statement

Operating cash flow (ttm)24.35B
Levered free cash flow (ttm)-12.93B